Statement regarding GBS alert in Peru
Statement regarding GBS alert in Peru July 10, 2023 The Foundation and its Global Medical Advisory Board are aware that Peru has issued a statement of emergency due to an increase in cases of Guillain Barre Syndrome. Please know we are here for you and the GBS|CIDP Foundation International is committed to addressing your concerns…
UnitedHealthcare dropping four immunoglobulin products from formulary
UnitedHealthcare (UHC), a private insurance company that provides health insurance to more than 25 million Americans nationwide, will be dropping four immunoglobulin (Ig) products from its formulary on October 1, 2023: Asceniv, Cuvitru, Cutaquig, and Panzyga. These formulary changes will affect individual UnitedHealthcare plans (i.e., those obtained through a marketplace) except in Massachusetts, Nevada, and New York. It is…
September Hill Visit
In anticipation of the Foundation’s most recent iteration of our Medicare IVIG Access Enhancement Act being introduced in the House of Representatives in the coming days, Foundation staff Chelsey Fix and Ellie Herman went down to Capitol Hill for a day of on-the-ground advocacy. Joined by Health and Medicine Counsel staff, they met with 6…
Tips and Tricks for Traveling
The Coffee Chat, Tips and Tricks for Traveling, hosted by Foundation staff members Kelly McCoy and Lori Besiege, offered valuable support on how to navigate the challenges that may arise while you are on a plane, train, or bus with a neurological condition that may cause mobility issues. Whether you are traveling to our International…
ARDA Multifocal Motor Neuropathy Study Clinical Trial
ARDA Multifocal Motor Neuropathy Study The ARDA study is designed to assess the safety and effectiveness of the investigational study drug compared to a placebo for the treatment of adults living with MMN. Participants enrolled in the study will be randomly assigned by a computer to either receive the investigational drug or a placebo. Participants…
International Guillain-Barré Syndrome Outcome Study (IGOS) Clinical Trial
International Guillain-Barré Syndrome Outcome Study (IGOS) The international GBS Outcome Study (IGOS) is the largest and longest prospective trial designed to collect extensive data from patients afflicted with GBS in a systematic manner. The aim is to collect information from patients by intensive international collaboration. All patients are followed at standard intervals from the earliest…
Clinical Study of ANX005 and IVIG
A Clinical Study of ANX005 and IVIG in Subjects with Guillain Barré Syndrome (GBS) A Phase 1b Study to Evaluate the Safety, Tolerability and Drug-Drug Interactions of ANX005 and Intravenous Immunoglobulin (IVIg) in Subjects With Guillain Barré Syndrome CLICK HERE FOR MORE INFORMATION ON THE CURRENT TRIAL VIA CLINICALTRIALS.GOV
CIDP Clinical Trial
Open-Label Phase 2 study with SAR445088, a Complement C1s inhibitor, in adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), sponsored by Sanofi This global multicenter study will evaluate the efficacy, safety and tolerability of SAR445088 in CIDP. SAR445088 (previously known as BIVV020) is an investigational monoclonal antibody that targets Complement C1s and has a subcutaneous route…
Pediatric CIDP Clinical Trial
Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP CSL Behring is conducting an open-label study to investigate the efficacy of single and multiple-dose Privigen administration in IVIG‑pretreated and IVIG-untreated pediatric subjects with chronic inflammatory demyelinating polyneuropathy (CIDP). ClinicalTrials.gov Identifier: NCT03684018 CLICK HERE FOR MORE INFORMATION ON THE CURRENT TRIAL VIA CLINICALTRIALS.GOV
Clinical Trials
A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder that Affects the Peripheral Nerves) (ADHERE) *No Longer Recruiting* This is a phase 2 study to evaluate the safety and efficacy of the subcutaneous formulation of efgartigimod in adults with…
Foundation Co-hosts Open House with Bryn Mawr Rehab
In July of 2023, the Foundation co-hosted an Open House with Bryn Mawr Rehabilitation Hospital in Malvern, PA. GBS and CIDP patients in attendance received a guided tour of the facility from the PT and OT’s, as well as a demonstration of adaptive devices and recreational therapies. The feedback from our community has been very…
Volunteer spreads awareness in local hospitals
There is no greater force than like-minds joining together for a common mission to change lives. The Foundation volunteers continue to play an active role in our community by raising awareness of GBS, CIDP, MMN, and the Foundation resources. Ray Lopez, Boca Raton Liaison, has made it his mission to visit local hospitals and share…
Taking Volunteering to the Next Level
Taking Volunteering to the Next Level The Foundation volunteers are taking volunteering to a whole new level! Don’t miss a chance to tune into what our current volunteers are doing in the community. There is no greater force than like-minds joining together for a common mission to change lives. The Foundation volunteers continue to play…
Research Poster Opportunity for GBS, CIDP, MMN Patient Symposium
We Invite You to Participate! As valued members of our medical community, we would like to inform you and your colleagues in training, residents, and fellows of a special opportunity to participate in the 2023 GBS|CIDP Foundation Patient Symposium, October 5-7 in Alexandria, VA. Poster Request Drs. Jeffrey Allen and Bart Jacobs, as Chair and…
Honorary INC Plenary Lecture Awarded to GBS|CIDP Foundation International
The Peripheral Nerve Society (PNS) is an international non-profit organization of scientists, physicians, and other healthcare providers working together to investigate and treat diseases of the peripheral nervous system. An Honorary INC Plenary Lecture Award was given to the GBS|CIDP Foundation by the Inflammatory Neuropathy Consortium at the PNS conference in Copenhagen. Peripheral Nerve Society…